90002-06-5

Basic information

• Product Name: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine
• Synonyms: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine;5-(Chloromethyl)-3-(pyridin-2-yl)-1,2,4-oxadiazole;Pyridine, 2-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]-
• CAS NO: 90002-06-5
• Molecular Formula: C₈H₆ClN₃O
• Molecular Weight: 195.61
• Mol File: 90002-06-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 84-85 °C
• Boiling Point: 348.7°Cat760mmHg
• Flash Point: 164.7°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: 2-8°C
• PKA: -1.94±0.19(Predicted)
• CAS DataBase Reference: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine(90002-06-5)
• EPA Substance Registry System: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine(90002-06-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 90002-06-5(Hazardous Substances Data)

Usage

General Description

2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine is a complex organic compound featuring a pyridine ring - a six-membered ring structure comprising five carbon atoms and one nitrogen atom. The ring is substituted with a 1,2,4-oxadiazole moiety and a chloromethyl group; the presence of this chloromethyl group suggests that this compound may act as a chloromethylating agent, possibly participating in chemical reactions as an electrophile. This chemical is typical of those found in advanced chemical research and synthetic applications, though specific uses or reactions involving this particular compound aren't immediately apparent from its name alone. Its detailed properties such as boiling point, melting point, and exact reactivity profile would need to be sourced from specific data sheets or experimental literature.

InChI:InChI=1/C8H6ClN3O/c9-5-7-11-8(12-13-7)6-3-1-2-4-10-6/h1-4H,5H2

Upstream product

• 1772-01-6 (Z)-N'-hydroxy-pyridine-2-carboxamidine 
• 79-04-9 chloroacetyl chloride 
• 100-70-9 2-Cyanopyridine 
• 1401223-71-9 C₈H₈ClN₃O₂ 
• 749932-24-9 (Z)-N'-(2-chloroacetoxy)picolinimidamide 
• 749932-24-9 N-chloroacetoxy-pyridine-2-carboximidic acid amide 
• 1772-01-6 2-pyridylamidoxime 

Downstream Products

• 1401223-16-2 N-isopropyl-N-((3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-2-(p-tolyloxy)acetamide 

Relevant articles and documents

Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors

Screening of the 50 000 ChemBridge compound library led to the identification of the oxadiazole-isopropylamide 1 (PI-1833) which inhibited chymotrypsin-like (CT-L) activity (IC50 = 0.60 μM) with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L). LC-MS/MS and dialysis show that 1 is a noncovalent and rapidly reversible CT-L inhibitor. Focused library synthesis provided 11ad (PI-1840) with CT-L activity (IC50 = 27 nM). Detailed SAR studies indicate that the amide moiety and the two phenyl rings are sensitive toward modifications. Hydrophobic residues, such as propyl or butyl in the para position (not ortho or meta) of the A-ring and a m-pyridyl group as B-ring, significantly improve activity. Compound 11ad (IC50 = 0.37 μM) is more potent than 1 (IC50 = 3.5 μM) at inhibiting CT-L activity in intact MDA-MB-468 human breast cancer cells and inhibiting their survival. The activity of 11ad warrants further preclinical investigation of this class as noncovalent proteasome inhibitors.

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.